Related references
Note: Only part of the references are listed.Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer
Derek Wilke et al.
PHARMACOTHERAPY (2018)
Using Medical Claims Analyses to Understand Interventions for Parkinson Patients
Bastiaan R. Bloem et al.
JOURNAL OF PARKINSONS DISEASE (2018)
Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone
Lucas Regis et al.
PROSTATE (2017)
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
Julia Wilkerson et al.
LANCET ONCOLOGY (2017)
Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study
Guangjie Ji et al.
MEDICINE (2017)
Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer
Chaiyut Kongseang et al.
PROSTATE INTERNATIONAL (2017)
MATHEMATICAL MODELING OF CONTINUOUS AND INTERMITTENT ANDROGEN SUPPRESSION FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
Alacia M. Voth et al.
MATHEMATICAL BIOSCIENCES AND ENGINEERING (2017)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A review of disease progression models of Parkinson's disease and applications in clinical trials
Charles S. Venuto et al.
MOVEMENT DISORDERS (2016)
Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases
Eberhard Varenhorst et al.
CANCER MEDICINE (2016)
Racial Differences in the Diagnosis and Treatment of Prostate Cancer
Giuliano Di Pietro et al.
INTERNATIONAL NEUROUROLOGY JOURNAL (2016)
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
K. Fizazi et al.
ANNALS OF ONCOLOGY (2015)
Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
Kyung Seok Han et al.
YONSEI MEDICAL JOURNAL (2015)
Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group
Fernando Calais da Silva et al.
EUROPEAN UROLOGY (2014)
Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Predictive Clinical Indicators of Biochemical Progression in Advanced Prostate Cancer Patients Receiving Leuplin Depot as Androgen Deprivation Therapy
Chien-Hua Chen et al.
PLOS ONE (2014)
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Nima Sharifi
ENDOCRINOLOGY (2013)
Adaptation and clonal selection models of castration-resistant prostate cancer: Current perspective
Muhammed Ahmed et al.
INTERNATIONAL JOURNAL OF UROLOGY (2013)
Tumour heterogeneity and cancer cell plasticity
Corbin E. Meacham et al.
NATURE (2013)
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Juanita M. Crook et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men With Progressive Castration-Resistant Nonmetastatic Prostate Cancer
Matthew R. Smith et al.
CANCER (2011)
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
Chee M. Ng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta(1) integrin monoclonal antibody (volociximab) in cancer patients
Chee M. Ng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
An update on androgen deprivation therapy for prostate cancer
Nima Sharifi et al.
ENDOCRINE-RELATED CANCER (2010)
Molecular genetics of prostate cancer: new prospects for old challenges
Michael M. Shen et al.
GENES & DEVELOPMENT (2010)
Serum Prostate-Specific Antigen Levels Reflect the Androgen Milieu in Patients With Localized Prostate Cancer Receiving Androgen Deprivation Therapy: Tumor Malignant Potential and Androgen Milieu
Itsuhiro Takizawa et al.
PROSTATE (2010)
Decreasing Use of Luteinizing Hormone-Releasing Hormone Agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration Claims Analysis
Steven L. Chang et al.
JOURNAL OF UROLOGY (2009)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Catharine M. Sturgeon et al.
CLINICAL CHEMISTRY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Hans Lilja et al.
NATURE REVIEWS CANCER (2008)
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2007)
Monitoring of prostate cancer patients: Guidelines and current practice
Laurent Boccon-Gibod
EUROPEAN UROLOGY SUPPLEMENTS (2007)
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treared with chemotherapy
Timothy J. Daskivich et al.
UROLOGY (2007)
Personalized medicine: Elusive dream or imminent reality?
L. J. Lesko
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline
D. Andrew Loblaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples
Robert J. Bauer et al.
AAPS JOURNAL (2007)
Challenges of using medical insurance claims data for utilization analysis
Patrick T. Tyree et al.
AMERICAN JOURNAL OF MEDICAL QUALITY (2006)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
CM Ng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis
CM Ng et al.
PHARMACEUTICAL RESEARCH (2005)
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
O Smaletz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Ways to fit a PK model with some data below the quantification limit
SL Beal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test
KG Kowalski et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Share Paper
